Leukocare AG is an established industry partner for biotech and pharmaceutical companies, specializing in solving complex formulation challenges for sterile injectables.

For more than 20 years, Leukocare has worked with teams developing advanced biologics—such as multispecifics, ADCs, viral vectors, and ATMPs—where standard approaches often fall short. Each year, the company supports over 40 projects, enabling partners to confidently advance their drug products toward clinical development and regulatory submission.

Leukocare combines deep formulation expertise with a data-driven platform approach. By integrating molecular modeling and machine learning for smart excipient selection, the company reduces experimental workload and enables faster, unbiased decision-making. This approach allows for the efficient development of stable, high-quality formulations tailored to each molecule.

At the BIO International Convention, Leukocare will showcase how its collaborative and data-driven approach helps accelerate the development of complex biologics and derisk formulation strategies.